Related Experiment Video
Updated: Dec 25, 2025
08:26
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
12.4K
miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta
Mahsa Tahmasebivand1, Seyyed Reza Mousavi1, Mehdi Khorrami2
1Immunology research center, Tabriz University of medical science, Tabriz, Iran; Department of Medical Genetics, Faculty of Medicine, Tabriz university of Medical Sciences, Tabriz, Iran.
Journal of Neuroimmunology
|March 22, 2020
Summary
MicroRNA-504 (miR-504) may predict response to interferon-beta (IFN-β) therapy in multiple sclerosis (MS). Higher miR-504 levels indicate a better response, aiding early treatment decisions for MS patients.
Area of Science:
- Neuroimmunology
- Molecular Biology
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) is an immune-mediated central nervous system disorder causing demyelination.
- Interferon-beta (IFN-β) is a primary treatment for MS, but predicting patient response is crucial.
- Early identification of non-responders to IFN-β therapy is needed to prevent disease progression.
Purpose of the Study:
- To investigate microRNAs (miRNAs) as potential biomarkers for predicting IFN-β therapy response in MS patients.
- To analyze the expression levels of miR-504 and miR-711 in responders versus non-responders to IFN-β.
- To identify associated molecular signaling pathways using in-silico analysis.
Main Methods:
- Expression analysis of miR-504 and miR-711 in 52 IFN-β responder and 53 non-responder MS patients.
- In-silico analysis to determine enriched KEGG signaling pathways.
- Statistical comparison of miRNA expression levels between patient groups.
Main Results:
- miR-504 expression was significantly higher in patients who responded to IFN-β therapy compared to non-responders.
- Statistically significant KEGG molecular signaling pathways were identified.
- No significant difference was found for miR-711 (implied, as only miR-504 is highlighted).
Conclusions:
- miR-504 shows potential as a novel predictive biomarker for IFN-β therapy response in multiple sclerosis.
- This finding could facilitate personalized treatment strategies for MS patients.
- Further validation is warranted to establish miR-504 as a clinical biomarker.
